E-GEOD-43025 - Transcriptional profiles of Campylobacter jejuni macrolide resistant strain JL272 to 4mg/L erythromycin treatment
Released on 10 October 2013, last updated on 13 May 2014
Erythromycin is the drug of choice to treat campylobacteriosis, but resistance to this antibiotic is rising. The adaptive mechanisms employed by Campylobacter jejuni to erythromycin treatment remain unknown. The aim of this study is to determine the molecular basis underlying Campylobacter’s immediate response to Ery treatment. The design utilized an available two color microarray slide for the entire transcriptome of Campylobacter jejuni macrolide resistant strain JL272. One hybridizations were performed: sham-treated JL272 v.s. lethal dose erythromycin treated JL272. Samples were independently grown and harvested. There were three biological replicates of each sample.
transcription profiling by array
Qingqing Xia <email@example.com>, Qijing Zhang, Zuowei Wu
Adaptive mechanisms of Campylobacter jejuni to erythromycin treatment. Xia Q, Muraoka WT, Shen Z, Sahin O, Wang H, Wu Z, Liu P, Zhang Q. , Europe PMC 23767761